Dietrich John Pauls - Jun 1, 2022 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role
President and CEO, Director
Signature
/s/ Amy Culbert, attorney-in-fact
Stock symbol
DMAC
Transactions as of
Jun 1, 2022
Transactions value $
$0
Form type
4
Date filed
6/2/2022, 05:06 PM
Previous filing
Aug 16, 2021
Next filing
Nov 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding DMAC Voting Common Shares, no par value per share 35.8K Jun 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMAC Stock Option (right to buy) Award $0 +177K $0.00 177K Jun 1, 2022 Common Shares 177K $2.45 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.
F2 Vests with respect to 25% of the underlying common shares on June 1, 2023 and with respect to the remaining 75% of the underlying common shares in 36 as nearly equal as possible monthly installments commencing on July 1, 2023.